Selene E. Di Carlo

Selene E. Di Carlo

Auto-generated profile, based on publicly available information

Selene E. Di Carlo

Unité Stroma, Inflammation & Tissue Repair, Institut Pasteur, 75724 Paris, France; INSERM U1224, 75724 Paris, France

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2012 in Nature Medicine
Verified
Journal Article
Closed access
SDSophie Dulauroy
Sophie Dulauroy
SCSelene E Di Carlo
Selene E Di Carlo
FLFrancina Langa
Francina Langa
GEGérard Eberl
Gérard Eberl
LPLucie Peduto
Lucie Peduto

2 January 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SCSelene E. Di Carlo
Selene E. Di Carlo
LPLucie Peduto
Lucie Peduto
The ability to repair tissues is essential for the survival of organisms. In chronic settings, the failure of the repair process to terminate results in overproduction of collagen, a pathology known as fibrosis, which compromises organ recovery and impairs function. The origin of the collagen-overproducing cell has been debated for years. Here we review recent insights gained from the use of lineage tracing approaches in several organs. The resulting evidence points toward specific subsets of tissue-resident mesenchymal cells, mainly localized in a perivascular position, as the major source for collagen-producing cells after injury. We discuss these findings in view of the functional heterogeneity of mesenchymal cells of the perivascular niche, which have essential vascular, immune, and regenerative functions that need to be preserved for efficient repair.

16 April 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
VSVenturina Stagni
Venturina Stagni
IMIsabella Manni
Isabella Manni
VOVeronica Oropallo
Veronica Oropallo
MMMarcella Mottolese
Marcella Mottolese
ABAnna Di Benedetto
Anna Di Benedetto
DBDaniela Barilà
Daniela Barilà
ATM kinase preserves genomic stability by acting as a tumour suppressor. However, its identification as a component of several signalling networks suggests a dualism for ATM in cancer. Here we report that ATM expression and activity promotes HER2-dependent tumorigenicity in vitro and in vivo. We reveal a correlation between ATM activation and the reduced time to recurrence in patients diagnosed with invasive HER2-positive breast cancer. Furthermore, we identify ATM as a novel modulator of HER2 protein stability that acts by promoting a complex of HER2 with the chaperone HSP90, therefore preventing HER2 ubiquitination and degradation. As a consequence, ATM sustains AKT activation downstream of HER2 and may modulate the response to therapeutic approaches, suggesting that the status of ATM activity may be informative for the treatment and prognosis of HER2-positive tumours. Our findings provide evidence for ATM’s tumorigenic potential revising the canonical role of ATM as a pure tumour suppressor.

18 December 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
RLRossella Loria
Rossella Loria
GBGiulia Bon
Giulia Bon
VPValentina Perotti
Valentina Perotti
EGEnzo Gallo
Enzo Gallo
IBIlaria Bersani
Ilaria Bersani
RFRita Falcioni
Rita Falcioni
We used whole genome microarray analysis to identify potential candidate genes with differential expression in BRAFV600E vs NRASQ61R melanoma cells. We selected, for comparison, a peculiar model based on melanoma clones, isolated from a single tumor characterized by mutually exclusive expression of BRAFV600E and NRASQ61R in different cells. This effort led us to identify two genes, SEMA6A and MICAL1, highly expressed in BRAF-mutant vs NRAS-mutant clones. Real-time PCR, Western blot and immunohistochemistry confirmed preferential expression of Sema6A and Mical1 in BRAFV600E melanoma. Sema6A is a member of the semaphorin family, and it complexes with the plexins to regulate actin cytoskeleton, motility and cell proliferation. Silencing of Sema6A in BRAF-mutant cells caused cytoskeletal remodeling, and loss of stress fibers, that in turn induced cell death. Furthermore, Sema6A depletion caused loss of anchorage-independent growth, inhibition of chemotaxis and invasion. Forced Sema6A overexpression, in NRASQ61R clones, induced anchorage-independent growth, and a significant increase of invasiveness. Mical1, that links Sema/PlexinA signaling, is also a negative regulator of apoptosis. Indeed, Mical-1 depletion in BRAF mutant cells restored MST-1-dependent NDR phosphorylation and promoted a rapid and massive NDR-dependent apoptosis. Overall, our data suggest that Sema6A and Mical1 may represent new potential therapeutic targets in BRAFV600E melanoma.

15 July 2009 in Cancer Research
Verified
Journal Article
Closed access
PDF file
GBGiulia Bon
Giulia Bon
SCSelene E. Di Carlo
Selene E. Di Carlo
VFValentina Folgiero
Valentina Folgiero
PAPaolo Avetrani
Paolo Avetrani
CLChiara Lazzari
Chiara Lazzari
RFRita Falcioni
Rita Falcioni
Increased expression of α6β4 integrin in several epithelial cancers promotes tumor progression; however, the mechanism underlying its transcriptional regulation remains unclear. Here, we show that depletion of homeodomain-interacting protein kinase 2 (HIPK2) activates β4 transcription that results in a strong increase of β4-dependent mitogen-activated protein kinase and Akt phosphorylation, anchorage-independent growth, and invasion. In contrast, stabilization of HIPK2 represses β4 expression in wild-type p53 (wtp53)-expressing cells but not in p53-null cells or cells expressing mutant p53, indicating that HIPK2 requires a wtp53 to inhibit β4 transcription. Consistent with our in vitro findings, a strong correlation between β4 overexpression and HIPK2 inactivation by cytoplasmic relocalization was observed in wtp53-expressing human breast carcinomas. Under loss of function of HIPK2 or p53, the p53 family members TAp63 and TAp73 strongly activate β4 transcription. These data, by revealing that β4 expression is transcriptionally repressed in tumors by HIPK2 and p53 to impair β4-dependent tumor progression, suggest that loss of p53 function favors the formation of coactivator complex with the TA members of the p53 family to allow β4 transcription. [Cancer Res 2009;69(14):5978–86]

13 February 2008 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VFValentina Folgiero
Valentina Folgiero
PAPaolo Avetrani
Paolo Avetrani
GBGiulia Bon
Giulia Bon
SCSelene E. Di Carlo
Selene E. Di Carlo
AFAlessandra Fabi
Alessandra Fabi
RFRita Falcioni
Rita Falcioni
Tamoxifen is still the most widely used drug in hormone therapy for the treatment of breast cancer. Its benefits in adjuvant treatment are well documented in controlled and randomized clinical studies, which have demonstrated an increase in disease-free intervals of patients with positive hormonal receptors. However, the mechanisms involved in endocrine resistance are not clear. Laboratory and clinical data now indicate that bi-directional molecular cross-talk between nuclear or membrane ER and growth factor receptor pathways may be involved in endocrine resistance. We recently found a functional interaction between α6β4 integrin and ErbB-3 receptor to maintain the PI3K/Akt survival pathway of mammary tumour cells. We sought to improve understanding of this process in order to provide the involvement of both receptors insight into mechanism of Tamoxifen resistance. Using human breast cancer cell lines displaying different levels of α6β4 and ErbB-3 receptors and a series of 232 breast cancer biopsies from patients submitted to adjuvant Tamoxifen monotherapy for five years, we evaluated the functional interaction between both receptors in relationship to Tamoxifen responsiveness. In mammary carcinoma cells, we evidenced that the α6β4 integrin strongly influence Akt phosphorylation through ErbB-3 protein regulation. Moreover, the ErbB-3 inactivation inhibits Akt phosphorylation, induces apoptosis and inhibits in vitro invasion favouring Tamoxifen responsiveness. The analysis of human tumors revealed a significant relationship between α6β4 and ErbB-3 in P-Akt-positive and ERβ1-negative breast cancers derived from patients with lower disease free survival. We provided evidence that a strong relationship occurs between α6β4 and ErbB-3 positivity in ERβ1-negative breast cancers. We also found that the association between ErbB-3 and P-Akt positivity mainly occurs in ERβ1-negative breast cancer derived from patients with lower DFS indicating that both receptors are clinically relevant in predicting the response to Tamoxifen.